课题基金 / 基金详情

项目摘要

项目成果

KOJO A. MENSA-WILMOT的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Protein kinases are important regulators of cell proliferation, migration, and differentiation. Cancer cells of many types over-express protein kinases. Drugs that inhibit specific protein kinases are now used to treat some human cancers. Anti-parasite drug discovery receives almost no support from the pharmaceutical industry, because the clients for the drugs are poor. "Alternative Use" drug discovery, which involves testing of drugs approved for control of non-parasitic diseases as treatment for parasite infections is a cost-effective and fast route for finding new lead compounds that may be studied further as anti-parasite drugs. Novel drugs are needed for treatment of human African trypanosomiasis, which is caused by the protozoan parasite Trypanosoma brucei. Our preliminary bioinformatic and pharmacological studies indicate that some protein kinases are important for viability and may be targeted for drug discovery in T. brucei. In Specific Aim 1, we will perform a "focused screen" of drugs that inhibit protein kinases to find out which of them kill blood stream form T. brucei in culture. Promising anti-trypanosome lead compounds will be evaluated further in a mouse model of T. brucei infection. In Specific Aim 2, we will validate the target of the protein kinase inhibitors, using a combination of affinity chromatography/chemical proteomics and molecular genetics approaches. Data from these exploratory/developmental (R21) studies will provide new lead compounds for anti-trypanosome drug discovery, and form the basis for a future work to delineate the biological relevance of protein kinase signaling in T. brucei. PUBLIC HEALTH RELEVANCE: Trypanosomes cause diseases that affect millions of people world-wide. Work described in this proposal may lead to discovery of new drugs for treatment of human African trypanosomiasis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Hit-to-lead optimization for sleeping sickness drug discovery
  • 批准号:
    9751174
  • 项目类别:
  • 资助金额:
    $69.08万
  • 财政年份:
    2016
  • 负责人:
    KOJO A. MENSA-WILMOT
  • 依托单位:
Hit-to-lead optimization for sleeping sickness drug discovery
  • 批准号:
    9078330
  • 项目类别:
  • 资助金额:
    $64.03万
  • 财政年份:
    2016
  • 负责人:
    KOJO A. MENSA-WILMOT
  • 依托单位:
Lead Optimization of Lapatinib Analogs for Human African Trypanosomiasis
  • 批准号:
    8904898
  • 项目类别:
  • 资助金额:
    $67.25万
  • 财政年份:
    2014
  • 负责人:
    KOJO A. MENSA-WILMOT
  • 依托单位:
Development of HTS assay and screening paradigm to discover new kinase inhibitors
海外基金